Actinogen Medical Ltd has released a press release.
ACW AD trial amendment and Clinical Science Forum slides
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
In the deck
Earlier from Actinogen Medical
- Appendix 4D & Half-Year Financial Statements
- FDA agrees to six-month Phase 2b Alzheimers Disease Trial
- First patient treated in XanaCIDD Phase 2 Depression Trial
- R&D tax incentive rebate received
- ACW clinical biomarker study webcast presentation
Later from Actinogen Medical
- Quarterly Activity Report & Appendix 4C
- Actinogen announces $10 million rights offer
- Entitlement Offer Prospectus
- ACW secures shortfall commitments of $4.56m for rights issue
- ACW secures further $0.5m rights issue shortfall commitment
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical